4.7 Article

Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

期刊

CANCER DISCOVERY
卷 6, 期 11, 页码 1276-1291

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-0177

关键词

-

类别

资金

  1. National Research Foundation (NRF) Singapore through an NRF Fellowship [NRF-NRFF2012-054]
  2. Nanyang Technological University School of Biological Sciences
  3. NRF
  4. Ministry of Education, Singapore
  5. RNA Biology Center at the Cancer Science Institute of Singapore, NUS, Singapore Ministry of Education's Tier 3 grants
  6. Institute of Molecular and Cell Biology (IMCB), Singapore

向作者/读者索取更多资源

Cancer-specific TERT promoter mutations (-146C>T and -124C>T) have been linked to reactivation of the epigenetically silenced telomerase reverse transcriptase gene (TERT). Understanding how these single-nucleotide alterations drive TERT reactivation is a fundamental unanswered question and is key for making successful therapeutics. We show that unlike wild-type promoters, recruitment of the transcription factor GABPA specifically to mutant TERT promoters mediates long-range chromatin interaction and enrichment of active histone marks, and hence drives TERT transcription. CRISPR-mediated reversal of mutant TERT promoters, or deletion of its long-range interacting chromatin, abrogates GABPA binding and long-range interactions, leading to depletion of active histone marks, loss of POL2 recruitment, and suppression of TERT transcription. In contrast, de novo introduction of a TERT promoter mutation enables GABPA binding and upregulation of TERT via long-range interactions, acquisition of active histone marks, and subsequent POL2 recruitment. This study provides a unifying mechanistic insight into activation of mutant TERT promoters across various human cancers. SIGNIFICANCE: This study identifies a key mechanism by which cancer-specific mutant TERT promoters cause reactivation of TERT. Because the mechanism uncovered here is not utilized by promoters that drive TERT in normal cells, this mechanism could be exploited to make inhibitors which have the potential to block telomerase function and hence the progression of up to 90% of human cancers. (C)2016 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据